[go: up one dir, main page]

NO993776D0 - Gitte dinukleotider og deres anvendelse som modulatorer av mukociliaer renselse og ciliaer stötfrekvens - Google Patents

Gitte dinukleotider og deres anvendelse som modulatorer av mukociliaer renselse og ciliaer stötfrekvens

Info

Publication number
NO993776D0
NO993776D0 NO993776A NO993776A NO993776D0 NO 993776 D0 NO993776 D0 NO 993776D0 NO 993776 A NO993776 A NO 993776A NO 993776 A NO993776 A NO 993776A NO 993776 D0 NO993776 D0 NO 993776D0
Authority
NO
Norway
Prior art keywords
sub
useful
treatment
dinucleotides
mucocilia
Prior art date
Application number
NO993776A
Other languages
English (en)
Other versions
NO326718B1 (no
NO993776L (no
Inventor
William Pendergast
Benjamin R Yerxa
Janet L Rideout
Suhaib M Siddiqi
Original Assignee
Inspire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/797,472 external-priority patent/US5900407A/en
Priority claimed from US08/798,508 external-priority patent/US5837861A/en
Application filed by Inspire Pharmaceuticals Inc filed Critical Inspire Pharmaceuticals Inc
Publication of NO993776D0 publication Critical patent/NO993776D0/no
Publication of NO993776L publication Critical patent/NO993776L/no
Publication of NO326718B1 publication Critical patent/NO326718B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • C07H19/10Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/10Expectorants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/20Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
NO19993776A 1997-02-06 1999-08-04 Dinukleotider og farmasøytiske preparater omfattende slike, og anvendelser derav for fremstilling av medikamenter. NO326718B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/797,472 US5900407A (en) 1997-02-06 1997-02-06 Method of treating dry eye disease with uridine triphosphates and related compounds
US08/798,508 US5837861A (en) 1997-02-10 1997-02-10 Dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency
PCT/US1998/002702 WO1998034942A2 (en) 1997-02-06 1998-02-06 Dinucleotides and their use

Publications (3)

Publication Number Publication Date
NO993776D0 true NO993776D0 (no) 1999-08-04
NO993776L NO993776L (no) 1999-10-06
NO326718B1 NO326718B1 (no) 2009-02-02

Family

ID=27121880

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19993776A NO326718B1 (no) 1997-02-06 1999-08-04 Dinukleotider og farmasøytiske preparater omfattende slike, og anvendelser derav for fremstilling av medikamenter.

Country Status (16)

Country Link
US (2) US6348589B1 (no)
EP (1) EP0981534B1 (no)
JP (1) JP4531867B2 (no)
KR (1) KR100606131B1 (no)
CN (1) CN1262556C (no)
AT (1) ATE325129T1 (no)
AU (1) AU738907C (no)
BR (1) BR9807169A (no)
CA (1) CA2279963C (no)
DE (1) DE69834392T2 (no)
DK (1) DK0981534T3 (no)
ES (1) ES2264197T3 (no)
NO (1) NO326718B1 (no)
NZ (1) NZ337225A (no)
PT (1) PT981534E (no)
WO (1) WO1998034942A2 (no)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6673779B2 (en) 1996-03-27 2004-01-06 Inspire Pharmaceuticals, Inc. Method of treating ciliary dyskinesia with dinucleoside polyphosphate compounds or UTP analogues
US6319908B1 (en) 1996-07-03 2001-11-20 Inspire Pharmaceuticals, Inc. Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof
US5763447C1 (en) 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
ES2264197T3 (es) 1997-02-06 2006-12-16 Inspire Pharmaceuticals, Inc. Dinucleotidos y sus usos.
US7223744B2 (en) * 1997-02-10 2007-05-29 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof
US6818629B2 (en) * 1997-02-10 2004-11-16 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising P1-(2'-deoxycytidine 5'-)P4-(uridine 5'-) tetraphosphate
US7078391B2 (en) * 1997-02-10 2006-07-18 Inspire Pharmaceuticals, Inc. Method of treating edematous retinal disorders
US6596725B2 (en) * 1997-02-10 2003-07-22 Inspire Pharmaceuticals, Inc. Use of certain dinucleotides to stimulate removal of fluid in retinal detachment and retinal edema
US6548658B2 (en) * 1997-07-25 2003-04-15 Inspire Pharmaceuticals, Inc. Di-(uridine 5′)-tetraphosphate and salts thereof
DK1012154T3 (da) 1997-07-25 2004-07-26 Inspire Pharmaceuticals Inc Salte af di(uridin-5'-tetraphosphat), fremgangsmåde til fremstilling og anvendelser deraf
US6872710B2 (en) * 1997-07-25 2005-03-29 Inspire Pharmaceuticals, Inc. Di(uridine 5′)-tetraphosphate and salts thereof
US6462028B2 (en) 1997-07-25 2002-10-08 Inspire Pharmaceuticals, Inc. Method of promoting cervical and vaginal secretions
TW593331B (en) 1997-07-25 2004-06-21 Inspire Pharmaceuticals Inc Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof
ATE288273T1 (de) * 1997-08-29 2005-02-15 Univ North Carolina Verwendung von uridin-5'-diphosphat und analoge zur behandlung von lungenerkrankungen
JP4633927B2 (ja) * 1998-05-22 2011-02-16 インスパイアー ファーマシューティカルズ,インコーポレイティド 治療用ジヌクレオチドおよび誘導体
WO2000039145A1 (en) * 1998-12-23 2000-07-06 The University Of North Carolina At Chapel Hill Targeted gene transfer using g protein coupled receptors
AU3612600A (en) 1999-02-26 2000-09-14 Inspire Pharmaceuticals, Inc. Method of promoting mucosal hydration with certain uridine, adenine and cytidine diphosphates and analogs thereof
EA004707B1 (ru) * 1999-06-30 2004-06-24 Ямаса Корпорейшн Кристаллы динуклеотида
AU6551800A (en) * 1999-08-17 2001-03-13 Adani, Alexander Dinucleoside 5',5'-tetraphosphates as inhibitors of viral reverse transcriptasesand viruses
MXPA02005161A (es) * 1999-12-22 2002-12-09 Inspire Pharmaceuticals Inc Metodo para tratamiento de enfermedades del aparato gastrointestinal con agonistas de los receptores purinergicos.
RU2161982C1 (ru) * 2000-01-20 2001-01-20 Общество с ограниченной ответственностью "Клиника Института биорегуляции и геронтологии" Тетрапептид, стимулирующий функцию сетчатой оболочки глаза, фармакологическое средство на его основе и способ его применения
US6864243B1 (en) 2000-05-12 2005-03-08 Inspire Pharmaceuticals, Inc. Method for treating retinal degeneration with purinergic receptor agonists
EP1428538B1 (en) 2000-05-30 2013-08-14 Santen Pharmaceutical Co., Ltd Ectocornea extension promoters
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7452870B2 (en) 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US6867199B2 (en) 2000-08-21 2005-03-15 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapeutic use
US6555675B2 (en) * 2000-08-21 2003-04-29 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapuetic use as purinergic receptor agonists
US7132408B2 (en) * 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7115585B2 (en) * 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
EP1366055A2 (en) * 2000-12-15 2003-12-03 Pharmasset Limited Antiviral agents for treatment of flaviviridae infections
US20040122223A1 (en) * 2001-02-07 2004-06-24 Davis Jeremy Martin Non-natural nucleotides and dinucleotides
US7109181B2 (en) 2001-06-25 2006-09-19 Inspire Pharmaceuticals, Inc. Joint lubrication with P2Y purinergic receptor agonists
EP1409503A1 (en) * 2001-07-25 2004-04-21 Celltech R & D Limited Non-natural carbon-linked nucleotides and dinucleotides
US20030109488A1 (en) * 2001-10-11 2003-06-12 Alcon, Inc. Methods for treating dry eye
US7256183B2 (en) 2001-11-06 2007-08-14 Inspire Pharmaceuticals, Inc. Method for treating or preventing inflammatory diseases
US7084128B2 (en) 2002-01-18 2006-08-01 Inspire Pharmaceuticals, Inc. Method for reducing intraocular pressure
WO2004037167A2 (en) * 2002-10-18 2004-05-06 Molichem Medicines, Inc. Methods of treating dry eye disease with lantibiotics
US6984628B2 (en) * 2003-07-15 2006-01-10 Allergan, Inc. Ophthalmic compositions comprising trefoil factor family peptides
EP1750740A4 (en) * 2004-05-06 2009-06-10 Molichem Medicines Inc TREATMENT OF MEMBRANE-ASSOCIATED DISEASES AND DISORDERS USING COMPOSITIONS CONTAINING LANTIBIOTICS
WO2005115432A2 (en) * 2004-05-06 2005-12-08 Molichem Medicines, Inc. Treatment of ocular diseases and disorders using lantibiotic compositions
GB0417886D0 (en) * 2004-08-11 2004-09-15 Univ Cardiff Method and means for enhanced pulmonary delivery
GB0502250D0 (en) * 2005-02-03 2005-03-09 Ic Vec Ltd Use
US7368439B2 (en) * 2005-06-15 2008-05-06 Bar - Ilan University Dinucleoside poly(borano)phosphate derivatives and uses thereof
US7851456B2 (en) * 2005-06-29 2010-12-14 Inspire Pharmaceuticals, Inc. P2Y6 receptor agonists for treating lung diseases
US20090306009A1 (en) 2005-12-06 2009-12-10 P2-Science Aps Modulation of the P2Y2 Receptor Pathway
US20070249556A1 (en) * 2006-04-21 2007-10-25 Brubaker Kurt E Method of treating inflammation
EP2045257B1 (en) 2006-07-26 2016-08-17 Yamasa Corporation Process for producing di(pyrimidine nucleoside 5'-)polyphosphate
EP2049665A2 (en) * 2006-07-28 2009-04-22 Applera Corporation Dinucleotide mrna cap analogs
EP2211956A4 (en) 2007-10-10 2014-07-09 Parion Sciences Inc DISPOSAL OF OSMOLYTES WITH A NOSE CANNULA
US8168597B2 (en) * 2008-10-22 2012-05-01 Inspire Pharmaceuticals, Inc. Method for treating cystic fibrosis
US9067964B2 (en) 2008-12-18 2015-06-30 Oligomer Sciences Ab Complex and method for enhancing nuclear delivery
US9011909B2 (en) 2010-09-03 2015-04-21 Wisconsin Pharmacal Company, Llc Prebiotic suppositories
BR112013005438B1 (pt) 2010-09-10 2021-09-21 Santen Pharmaceutical Co., Ltd Agente para o tratamento de olho ressecado caracterizado por combinar o agonista do receptor de p2y2 e ácido hialurônico ou um sal do mesmo, método para o tratamento de olho ressecado, e uso do agonista do receptor de p2y2, e ácido hialurônico ou um sal do mesmo
JP6219271B2 (ja) 2011-06-07 2017-10-25 パリオン・サイエンシィズ・インコーポレーテッド 治療の方法
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
KR101875845B1 (ko) 2012-03-26 2018-07-06 산텐 세이야꾸 가부시키가이샤 디쿠아포솔 함유 점안액
BR112014029329A2 (pt) 2012-05-29 2017-06-27 Parion Sciences Inc aminoamidas semelhantes ao dendrímero possuindo atividade bloqueadora de canal de sódio para o tratamento de olho seco e outras doenças mucosais
HUE032891T2 (hu) 2012-12-17 2017-11-28 Parion Sciences Inc Klórpirazin-karboxamid-származékok nem kielégítõ nyálkahártya-hidratáció által elõsegített megbetegedések kezelésére
ES2674665T3 (es) 2012-12-17 2018-07-03 Parion Sciences, Inc. Compuestos de 3,5-diamino-6-cloro-N-(N-(4-fenilbutilo)carbamimidoilo)-pirazina-2-carboxamida
EP2931712B8 (en) 2012-12-17 2018-05-23 Parion Sciences, Inc. 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
US10323058B2 (en) 2014-07-24 2019-06-18 W. R. Grace & Co.-Conn. Crystalline form of nicotinamide riboside
AU2016229319B2 (en) 2015-03-09 2020-05-07 W.R. Grace & Co.-Conn. Crystalline form of nicotinamide riboside
US20180125876A1 (en) * 2015-05-20 2018-05-10 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and Pharmaceutical Composition for Modulation Polarization and Activation of Macrophages
US11414407B2 (en) 2017-12-22 2022-08-16 Elysium Health, Inc. Crystalline forms of nicotinamide riboside chloride
EP3919062A1 (en) 2020-06-02 2021-12-08 Institut Gustave-Roussy Modulators of purinergic receptors and related immune checkpoint for treating acute respiratory distress syndrom
US20230302031A1 (en) 2020-06-02 2023-09-28 Institut Gustave-Roussy Modulators Of Purinergic Receptors and Related Immune Checkpoint For Treating Acute Respiratory Distress Syndrome

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4855304A (en) 1985-01-10 1989-08-08 Repligen Corporation Dinucleoside pyrophosphates and pyrophosphate homologs as plant antivirals
US5049550A (en) 1987-11-05 1991-09-17 Worcester Foundation For Experimental Biology Diadenosine 5', 5'"-p1, p4,-tetraphosphate analogs as antithrombotic agents
US5292498A (en) * 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
IL114520A0 (en) 1994-07-15 1995-11-27 Lepetit Spa Dinucleoside-5',5',-pyrophosphates
US5635160A (en) 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US5837861A (en) * 1997-02-10 1998-11-17 Inspire Pharmaceuticals, Inc. Dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency
US5681823A (en) 1996-05-02 1997-10-28 Prp Inc. P1, P4 -dithio-P2 -P3 -monochloromethylene 5', 5'"-diadenosine P1, P4 -tetraphosphate as antithrombotic agent
US5789391A (en) 1996-07-03 1998-08-04 Inspire Pharmaceuticals, Inc. Method of treating sinusitis with uridine triphosphates and related compounds
US5763447C1 (en) 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
ES2225958T3 (es) 1996-10-09 2005-03-16 Pharmasset, Ltd. Compuestos bisfonato micofenolicos.
ES2264197T3 (es) 1997-02-06 2006-12-16 Inspire Pharmaceuticals, Inc. Dinucleotidos y sus usos.

Also Published As

Publication number Publication date
KR20000070807A (ko) 2000-11-25
EP0981534B1 (en) 2006-05-03
JP2001526635A (ja) 2001-12-18
ES2264197T3 (es) 2006-12-16
US20020082417A1 (en) 2002-06-27
AU738907B2 (en) 2001-09-27
AU738907C (en) 2002-05-16
WO1998034942A3 (en) 2000-01-06
NO326718B1 (no) 2009-02-02
DK0981534T3 (da) 2006-09-04
CN1262556C (zh) 2006-07-05
CN1292795A (zh) 2001-04-25
US6348589B1 (en) 2002-02-19
ATE325129T1 (de) 2006-06-15
DE69834392T2 (de) 2007-02-08
CA2279963A1 (en) 1998-08-13
AU6324298A (en) 1998-08-26
US6977246B2 (en) 2005-12-20
KR100606131B1 (ko) 2006-07-31
JP4531867B2 (ja) 2010-08-25
CA2279963C (en) 2008-04-22
WO1998034942A2 (en) 1998-08-13
NZ337225A (en) 2002-03-28
EP0981534A2 (en) 2000-03-01
DE69834392D1 (de) 2006-06-08
PT981534E (pt) 2006-09-29
BR9807169A (pt) 2000-06-06
NO993776L (no) 1999-10-06

Similar Documents

Publication Publication Date Title
NO993776D0 (no) Gitte dinukleotider og deres anvendelse som modulatorer av mukociliaer renselse og ciliaer stötfrekvens
WO1999061012A3 (en) Therapeutic dinucleotide and derivatives
AR011127A1 (es) COMPUESTOS DINUCLEoTIDOS, COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO PARA PREPARAR UN MEDICAMENTO
JP2002516273A5 (no)
AR013454A1 (es) Metodo para el tratamiento de las enfermedades pulmonares con 5'-difosfato de uridina y analogos del mismo, composiciones formuladas con dichos compuestosy los compuestos mencionados.
CY1106643T1 (el) Αναστολεις συνθεσης βλεννινης
SG146649A1 (en) Mucoactive agents for treating a pulmonary disease
NO20003038D0 (no) 4(3)Substituerte-4(3)-aminometyl-(tio)pyran eller - piperidinderivater (=gabapentinanaloger), deres fremstilling og deres anvendelse ved behandling av neurologiske lidelser
MXPA02011311A (es) Composicion novedosa.
BR9813028A (pt) Agonistas de prostaglandina e seu uso para tratar distúrbios nos ossos
IS6444A (is) Pýrimidín karboxamíð nytsamleg sem latar á PDE4 samsætuensím
CA2487365A1 (en) Piperidine derivatives as potassium channel blockers
US6555675B2 (en) Dinucleoside polyphosphate compositions and their therapuetic use as purinergic receptor agonists
PT1406667E (pt) Métodos para aumentar a eficácia in vivo de oligonucleótidos e a inibição da inflamação em mamíferos
WO2002070532A3 (en) C2,5'-disubstituted and n6,c2,5'-trisubstituted adenosine derivatives and their different uses
SE9900833D0 (sv) Novel combination
BG103959A (en) Carbocyclic nucleoside hemisulphate and its application in the treatment of viral infections
WO2002083167A3 (en) Therapeutic compositions for the treatment of a respiratory tract disease
SE9900834D0 (sv) Novel combination
US6867199B2 (en) Dinucleoside polyphosphate compositions and their therapeutic use
AU4335901A (en) Novel therapeutic treatment of chronic obstructive pulmonary disease
WO2003037309A3 (en) USE OF 4α PHORBOL
IT1281501B1 (it) Impiego di combinazioni di analoghi di nucleosidi nella terapia delle infezioni da virus dell'aids
AU2001251400A1 (en) Treatment of pulmonary disorders by inducing alveoli formation

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MERCK SHARP & DOHME CORP, US

MM1K Lapsed by not paying the annual fees